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Abstract
Gene delivery holds therapeutic promise for the treatment of neurological diseases and spi-
nal cord injury. Although several studies have investigated the use of non-viral vectors,
such as polyethylenimine (PEI), their clinical value is limited by their cytotoxicity. Recently,
biodegradable poly (lactide-co-glycolide) (PLGA) nanospheres have been explored as non-
viral vectors. Here, we show that modification of PLGA nanospheres with 3β-[N-(N0,N0-
dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) enhances gene transfection effi-
ciency. PLGA/DC-Chol nanospheres encapsulating DNA were prepared using a double
emulsion-solvent evaporation method. PLGA/DC-Chol nanospheres were less cytotoxic
than PEI both in vitro and in vivo. DC-Chol modification improved the uptake of nano-
spheres, thereby increasing their transfection efficiency in mouse neural stem cells in vitro
and rat spinal cord in vivo. Also, transgene expression induced by PLGA nanospheres was
higher and longer-lasting than that induced by PEI. In a rat model of spinal cord injury,
PLGA/DC-Chol nanospheres loaded with vascular endothelial growth factor gene
increased angiogenesis at the injury site, improved tissue regeneration, and resulted in bet-
ter recovery of locomotor function. These results suggest that DC-Chol-modified PLGA
nanospheres could serve as therapeutic gene delivery vehicles for spinal cord injury.
Introduction
The delivery of therapeutic genes has been developed as a potential treatment for central ner-
vous system injury [1,2]. The use of viral vectors to deliver genes has been in experimental ani-
mal models [3,4]. However, viral vectors induce a strong immune and inflammatory response,
limiting their clinical application [5,6]. In contrast to viral vectors, non-viral vectors such as
copolymers and cationic lipids and liposomes are advantageous due to their low toxicity, low
tendency to induce immune responses, high tissue-specific targeting, good ease and scale of
production, and good handling properties [7–9]. Although non-viral vectors have been
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proposed as alternatives to viral vectors, there is still a need to improve their low transfection
rates and gene expression efficiencies.
Several studies demonstrate that nanospheres formed from biodegradable poly (lactic-co-gly-
colic acid) (PLGA) copolymer are efficient vehicles for various types of therapeutic agents such as
drugs and genes [7,10–14]. PLGA is biocompatible and approved by the United States Food and
Drug Administration for human clinical use for a variety of applications such as surgical screws
and sutures [8]. PLGA nanospheres facilitate the sustained release of encapsulated plasmid DNA
(pDNA) and thus have the potential to direct long-term gene expression [12,15]. Due to their small
size, PLGA nanospheres are taken up by cells through endocytosis and are capable of endo-lysomal
escape. However, unmodified PLGA nanospheres have low gene transfection efficiency compared
to other delivery vehicles comprised of cationic lipids or polymers [16,17]. For this reason, cationic
excipients such as chitosan, polyethyleneimine (PEI), and cationic lipids and polyamines have been
added to PLGA-based gene delivery systems to improve their transfection properties.
Many cationic lipids in the form of liposomes show good gene transfer activity. The posi-
tively charged lipid binds to pDNA via electrostatic forces, leading to the formation of DNA-
lipid complexes that are taken up into cells by endocytosis [18]. Cationic lipids such as 3β-[N-
(N0,N0-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) or dioleoylphosphatidyletha-
nolamine (DOPE) have been extensively investigated in studies of gene delivery, with several
lipids having been tested in various stages of clinical trials [19] due to their low toxicity [20].
DC-Chol possesses a tertiary amine that is not ionized at neutral to alkaline pH levels; there-
fore, it reduces the aggregation of DNA-liposome complexes and leads to higher transgene
expression [21]. However, DC-Chol liposomes have several limitations, such as poor serum
stability and short circulation in vivo [22,23].
In this study, we investigated whether DC-Chol-modified PLGA nanospheres enable more
efficient gene delivery than unmodified PLGA nanospheres. First, we evaluated the physicochem-
ical and cytotoxic properties of PLGA/DC-Chol nanospheres. We investigated whether PLGA/
DC-Chol nanospheres enhance cellular uptake and gene expression in mouse neural stem cells
and enhance gene transfection efficiency after direct injection into the rat spinal cord. Also, we
evaluated the therapeutic efficacy of PLGA/DC-Chol nanospheres as delivery vehicles for the vas-
cular endothelial growth factor (VEGF) gene in a rat model of spinal cord injury.
Material and Methods
Nanosphere preparation
PLGA-hybrid nanospheres encapsulating pDNA were prepared using a double emulsion-sol-
vent evaporation method as previously described [7,16]. Briefly, 1 ml luciferase pDNA
(pSV-Luc) or pSV-VEGF in Tris/EDTA buffer was emulsified in a PLGA solution (5% w/v in
methylene chloride, MW = 66,000 Da; Birmingham Polymers, Birmingham, AL, USA) with or
without DC-Chol solution (5% w/v in methylene chloride, Birmingham) using a sonicator for
5 min. A water-in-oil solution was emulsified in 25 ml of 4% (w/v) aqueous polyvinyl alcohol
(PVA, MW = 30,000–70,000 Da; Sigma, St. Louis, Mo) solution using a sonicator for 5 min.
The emulsion was stirred for 72 h at room temperature to remove methylene chloride. PLGA
nanospheres were recovered by ultracentrifugation (20,000g for 20 min at 4°C). The PLGA
nanosphere pellet was washed five times in distilled water to remove PVA and was then re-sus-
pended by vortexing and lyophilizing for 48 h to obtain a dry powder.
Nanosphere characterization
Size distribution and zeta potential of nanospheres encapsulating the pSV-Luc gene were evalu-
ated using dynamic laser light scattering (Zetasizer 3000HS, Malvern, UK). Morphological
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examination of nanospheres was performed using a scanning electron microscope (SEM;
JSM6330F, JEOL, Tokyo, Japan). To determine the amount of pSV-Luc incorporated into
PLGA or PLGA/DC-Chol nanospheres, 10 mg of nanospheres encapsulating pSV-Luc were
dissolved in 0.5 ml of 0.5M NaOH while stirring at 37°C until a clear solution was obtained
[14,16]. pDNA content in the resulting solution was quantified by a UV spectrophotometer
(Shimadzu 1204, Tokyo, Japan) at 260 nm by means of a standard curve of pDNA in solution
of blank nanospheres dissolved NaOH.
Structural integrity of pDNA
pDNA extracted from nanospheres was analyzed by gel electrophoresis for purity and struc-
tural integrity before and after encapsulation. pDNA was extracted from nanospheres using
0.5N NaOH. Products were analyzed using 0.8% (w/v) agarose gel electrophoresis with ethid-
ium bromide staining. Gels were read using a gel documentation system (Gel Doc 1000, Bio-
Rad Laboratories, Hercules, CA, USA).
In vitro release of pDNA
To analyze the kinetics of pDNA release from PLGA or PLGA/DC-Chol nanospheres, pDNA-
loaded nanospheres were suspended in 2 ml phosphate-buffered saline (PBS, pH 7.4) at 37°C
under continuous agitation. The supernatant was then withdrawn, and PBS was replenished.
Amount of pDNA in the supernatant was determined with a UV spectrophotometer. Experi-
ments were performed in quintuplicate.
In vitro cytotoxicity
The cytotoxicity of PLGA nanospheres, PEI (MW = 25,000 Da; Sigma) or lipofectamine (Life
Technologies) was determined by measuring mitochondrial metabolic activity in cultured
mouse neural stem cells (mNSCs). mNSCs were plated in 96-well plates at 2×104 cells/well and
cultured for 24 h. Different concentrations of PLGA/DC-Chol nanospheres or PEI encapsulat-
ing pDNA were added to each well. After incubation for 4, 24, or 48 h at 37°C, mNSCs were
rinsed with PBS, and 200 μl MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bro-
mide, 2 mg/ml in PBS; Sigma) was added. After incubation for 4 h at 37°C, MTT solution was
removed. The resulting insoluble purple particles were dissolved in 100 μl dimethyl sulfoxide
hybrid-max (DMSO; Sigma) for 30 min, and absorbance was measured at 540 nm using an
ELISA plate reader. Percentage of cell metabolic activity was calculated by normalizing absor-
bance values with those of mNSCs not treated with polymer.
In vitro cellular uptake
To measure uptake of nanospheres by mNSCs, nanospheres containing pDNA and 50 mg fluo-
rescent dye (6-coumarin; Polysciences, Warrington, PA, USA) were prepared [7,16]. The solu-
tion of 6-coumarin in methylene chloride was mixed with PLGA/DC-Chol solubtion. A water-
in-oil solution was emulsified in 25 ml of 4% (w/v) aqueous polyvinyl alcohol (PVA) solution
using a sonicator for 5 min. The emulsion was stirred for 72 h to remove methylene chloride.
PLGA nanospheres were recovered by ultracentrifugation. The PLGA nanosphere pellet was
washed five times in distilled water and lyophilizing for 48 h to obtain a dry powder. mNSCs
were plated at 1×104 cells/well and allowed to attach for 24 h, after which nanospheres contain-
ing pDNA and fluorescent dye were added. After 6 or 24 h incubation at 37°C, the medium
was removed, and cells were washed with PBS. mNSCs were fixed in 4% (v/v) paraformalde-
hyde (PFA) at room temperature, and Vectashied mounting medium with DAPI (4,6-
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diamidino-2-phenylindole; Vector Laboratories) was used to stain cell nuclei. Cells transfected
with nanospheres were observed using confocal laser scanning microscopy (Fluoview BX50,
Olympus, Tokyo, Japan).
In vitro transfection
mNSCs were plated in 6-well plates at 2×105 cells/well and cultured for 24 h. pSV-Luc-encap-
sulating PLGA nanospheres or PEI (25,000 Da)/pSV-Luc complexes (the number of nitrogen
in PEI per DNA phosphate, N/P ratio = 5/1) were suspended in DMEM/F12, added to each
well at 2 μg pDNA/well, and incubated at 37°C. Afterward, the medium was changed to
DMEM/F12 supplemented with 10% (v/v) fetal bovine serum. The medium was changed every
2 days. Fourteen days after transfection, 100 μl lysis buffer (Cell Culture Lysis Reagent 5×, Pro-
mega, Madison, WI, USA) was added to each well. Lysates were incubated on ice and cleared
by centrifugation for 10 min at 13,000g using an ultracentrifuge. Transfection efficiency was
measured using a luminometer (TD20/20, Turner Design, Sunnyvale, CA, USA). Total protein
content in the supernatant was determined by a BCA protein assay kit (Pierce, Iselin, NJ).
Results are expressed as relative light units (RLU)/mg protein.
In vivo cytotoxicity
The spinal cord injury model involved adult male Sprague-Dawley rats (250–300 g; OrientBio
Gyeonggi-do, Korea). All procedures were approved by the Animal Care and Use Committee
of Yonsei University College of Medicine and were in accordance with international guidelines
on the ethical use of animals. The number of animals used was minimized. PLGA nanospheres,
PLGA/DC-Chol nanospheres, or PEI (25,000 Da)/pDNA complexes (N/P ratio:5/1) were
injected into the spinal cord of healthy rats. One day after transplantation, rats were sacrificed
and perfused with saline containing PFA (Merck, Germany). Apoptotic activity was measured
by TUNEL staining using the ApopTag Plus Fluorescein In situ Apoptosis Detection kit (Che-
micon International. Temecula, CA).
In vivo transfection
After anesthesia with sodium penthobarbital (20 mg/kg; Choongwae Pharma, Seoul, Korea),
laminectomy was performed at the T9 level. PLGA or PLGA/DC-Chol nanospheres encapsu-
lating pSV-Luc were immediately injected using an insulin syringe into the injured epicenter of
the spinal cord. In other groups of rats, PEI/pSV-Luc complex, naked pSV-Luc, or PBS was
injected into the injured epicenter spinal cord. After surgery, antibiotic sepazolin (50 mg/kg,
Yuhan Corporation) was administered for 7 days. Transgene expression in the spinal cord was
evaluated 14 days after surgery by a luciferase assay. Rats were sacrificed and perfused with
saline (pH 7.4), and the spinal cord including the epicenter was removed. Each specimen was
homogenized in lysis buffer (Cell Culture Lysis Reagent 5×, Promega, Madison, WI, USA) and
incubated on ice for 1 h. Samples were cleared by centrifugation for 10 min at 13,000g using an
ultracentrifuge. Transfection efficiency was measured using a luminometer (TD20/20, Turner
Design, Sunnyvale, CA, USA), and total protein content in the supernatants was determined
by BCA assay (Promega).
In vivo therapeutic effect
Rats were anesthetized with Zoletil 50 (10 mg/rat; Virbac. Carros, France), and laminectomy
was performed at the T9 level via clip compression for 10 min. PLGA/DC-Chol nanospheres
loaded with pSV-VEGF were immediately injected into the injured spinal cord with an insulin
DC-Chol/PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury
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syringe. In other groups of rats, PLGA/pSV-VEGF, PEI/pSV-VEGF complex, naked
pSV-VEGF, or PBS was injected into the injured spinal cord. Muscle and skin were closed
with sutures. After surgery, sepazolin (50 mg/kg; Yuhan Corporation) and bupreenorphin
(0.1mg/kg, Hanlim, Seoul, Korea) was administered for 7 days. Behavioral testing was per-
formed using the Basso, Beattie, Bresnahan (BBB) functional scale every week for 6 weeks.
Experimenters were blind to group identity of rats.
Immunofluorescent staining
Two or four weeks after injury and injection, rats were sacrificed and perfused with saline con-
taining 4% PFA (pH 7.4; Merck, Germany) to obtain spinal cord tissue. For histological analy-
ses, spinal cords were dissected and cut into 10 μm sections. Sections were stained using
fluorescently-tagged antibodies against neurofilament (NF; Abcam, Cambridge, MA), GFAP
(Abcam), or MAP-2 (Abcam). After obtaining images of the sections, Metamorph software
(Universal Imaging, West Chester, PA) was used to measure NF-positive areas. To analyze
microvessels, sections were stained using antibodies against SM-α actin (Abcam) followed by
FITC-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories). Twelve section
from each rat were randomly selected for quantification. Samples were analyzed using a laser
confocal microscope (LSM 700; Zeiss, Oberkochen, Germany).
Reverse transcription polymerase chain reaction (RT-PCR)
Total sample RNA from transfected cell (n = 6) or spinal cord (n = 5) was extracted using an
RNA extraction kit (Qiagen, Valencia, California, USA). Isolated RNA was converted to com-
plementary DNA (cDNA) using the AccuPower RTPReMix Kit (Bioneer Inc., Daejeon, South
Korea). Synthesized cDNA was amplified by PCR using the following primers: luciferase 50-
CAA ATC ATT CCG GAT ACT GCG-30 (forward), 50- GAA TTA CAC GGC GAT CTT TCC
-30 (reverse) and GAPDH 50- CAT GGT GGT GAA GAC GCC AG-30 (forward), 50-CCT CCT
CAT TGA CCT CAA CT—30 (reverse). PCR was carried out for 30 cycles of denaturation
(94°C, 30 s), annealing (55°C, 30 s), and extension (72°C, 45 s), with a final extension at 72°C
for 10 min. PCR products were visualized by electrophoresis on 1% (w/v) agarose gel with
ethidium bromide staining and analyzed using a gel documentation system (MiniBIS Pro; Bio-
imaging systems Ltd. Cambridge, UK).
Statistical analysis
Quantitative data were expressed as mean ± standard deviation (SD). Differences between
groups were analyzed by one-way analysis of variance (ANOVA). Newman-Keuls tests were
used for post-hoc comparisons between subgroups. Statistical analysis was performed using
Medcalc software. A p-value of less than 0.05 was considered statistically significant.
Results
Characterization of PLGA /DC-Chol nanospheres and their release
in vitro
Zeta potentials of nanospheres depended on their composition, with PLGA nanospheres con-
taining the highest amount of DC-Chol undergoing a negative–to-positive inversion of zeta
potential (Table 1). Scanning electron microphotographs showed that fabricated PLGA and
PLGA/DC-Chol nanospheres were discrete spheres without aggregation and smooth in surface
morphology (Fig 1A and 1B). PLGA/DC-Chol nanospheres were uniform in size. The average
diameter of PLGA and PLGA/DC-Chol nanospheres was 619 ± 45.5 and 444 ± 21.1 nm,
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respectively (Fig 1C). The average zeta potential of PLGA and PLGA/DC-Chol nanoparticles
was -34 ± 1.4 and 50.2 ± 8.7 mv, respectively (Fig 1D and 1E). The theoretical loading amount
was approximately 58 mg pDNA/mg of PLGA nanospheres, and pDNA loading efficiency was
68.2% ± 12.3 (n = 10). Gel electrophoresis assay for pDNA purity and structural integrity
before and after encapsulation by nanospheres revealed that the gel retardation pattern of
pDNA extracted from nanospheres was similar to that of un-complexed pDNA (Fig 1F). In
vitro pDNA release from PLGA and PLGA/DC-Chol nanospheres was sustained for at least 20
days (Fig 1G). The initial burst released approximately 35–40% of pDNA from nanospheres,
after which pDNA continued to be released for over 20 days. The sustained pDNA release at
later time points was due to the diffusion of DNA through the erosion of PLGA polymer.
Cytotoxicity and the cellular uptake of nanospheres and cytotoxicity
To visualize nanosphere uptake by mNSCs, cells were incubated with PLGA or PLGA
/DC-Chol nanospheres loaded with fluorescent dye for 6 or 24 h. After incubation, cells were
Table 1. Physiochemical characterization of PLGA/DC-Chol nanospheres.
Formulation DNA Loaded nanosphere
PLGA: DC-Chol Size (nm) Zeta (mV)
100:0 619 ± 45.5 -34 ± 1.4
100:10 553 ± 37.4 -4 ± 2.1
100:20 444 ± 21.1 50.2 ± 2.7
100:40 432 ± 19.8 56.1 ± 1.2
doi:10.1371/journal.pone.0147389.t001
Fig 1. Characterization of nanospheres. SEM images of (A) PLGA and (B) PLGA/DC-Chol nanospheres.
(C) Size distribution of nanospheres. Zeta potential (mV) of (D) PLGA and (E) PLGA/DC-Chol nanospheres.
(F) Agarose gel retardation analysis. Agarose gel electrophoresis of pDNA released from PLGA and PLGA/
DC-Chol nanospheres. (G) Cumulative release of pDNA from PLGA and PLGA/DC-Chol nanospheres.
doi:10.1371/journal.pone.0147389.g001
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washed with PBS to remove nanospheres on the cell surface so that only fluorescence from
internalized particles was measured [24]. After 6 h, cytoplasmic fluorescence was observed for
mNSCs treated with PLGA or PLGA/DC-Chol nanospheres (S1 Fig Top), with a higher inten-
sity of fluorescence for mNSCs treated with PLGA/DC-Chol nanospheres. After 24 h, mNSCs
treated with PLGA/DC-Chol nanospheres showed more intense fluorescence in the nuclei and
cytoplasm (S1 Fig Bottom), whereas mNSCs treated with PLGA nanospheres showed less
fluorescence.
To evaluate the cytotoxicity of nanospheres, mNSCs were treated with pSV-Luc-loaded
PLGA nanospheres, PLGA/DC-Chol nanospheres, or PEI. PLGA and PLGA/DC-Chol nano-
spheres were significantly less cytotoxic than the PEI complex at various concentrations and
incubation times (Fig 2A). PLGA/DC-Chol nanospheres produced similar levels of cytotoxicity
as PLGA nanospheres at all concentrations. The PEI complex, however, was more cytotoxic at
higher concentrations.
In vitro transfection
Concentrations of neurospheres were normalized to their pDNA contents. Cultured mNSCs
were incubated with 2 μg pSV-Luc/well, and expression of transgene delivered using PEI,
PLGA nanospheres, or PLGA/DC-Chol nanospheres was compared. After 7 days, transgene
expression was highest for PEI (Fig 2B and 2C). After 14 days, transgene expression decreased
Fig 2. (A) Cytotoxicity of pDNA-loaded nanospheres and PEI/pDNA complexes. mNSCs were cultured
for 4, 24, or 48 h with the indicated polymer concentrations, andmitochondrial metabolic activity in
mNSCs wasmeasured using the MTT assay. p < 0.05 for nanospheres (PLGA/DC-Chol or PLGA) vs.
PEI at all concentrations and time points (n = 5) except for 10 and 20 μg at 4 h. Transfection efficiency in
cultured mNSCs (B, C). (B) Luciferase gene expression in mNSCs transfected with pSV-Luc-loaded PLGA
nanospheres, PLGA/DC-Chol nanospheres, or PEI /pSV-Luc complex. *p < 0.05.PEI/pLuci compare with
naked, PLGA and PLGA/DC-Chol at 7 days after transfection. # p < 0.05 PLGA/DC-Chol nanospheres
compared with PLGA, PEI and naked at 14 days after transfection. **p < 0.05 PLGA nanospheres compared
with PEI and naked at 14 days after transfection. (C) Luciferase mRNA expression 7 and 14 days after gene
transfection.
doi:10.1371/journal.pone.0147389.g002
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for PEI but increased for PLGA and PLGA/DC-Chol nanospheres, with a 2-fold higher trans-
gene expression for PLGA/DC-Chol nanospheres compared with PLGA nanospheres. These
results indicate that although PEI resulted in higher transgene expression after 7 days,
DC-Chol enhanced the gene transfection efficiency of PLGA nanospheres 14 days after treat-
ment in vitro.
In vivo apoptosis in the rat spinal cord
One day after injection of naked pSV-Luc, PEI/pSV-Luc complex, PLGA/pSV-Luc nano-
spheres, or PLGA/DC-Chol/pSV-Luc nanospheres into healthy rat spinal cords, apoptosis was
assessed by TUNEL staining. There was significantly less TUNEL staining in PLGA/DC-Chol/
pSV-Luc spinal cords compared with PEI/pSV-Luc spinal cords (Fig 3A). The density of apo-
ptosis-positive cells in the spinal cord was significantly higher for the PEI/pSV-Luc group than
the other groups (Fig 3B).
In vivo gene expression in the rat spinal cord
To evaluate the persistence of gene expression, naked pSV-Luc, PEI/pSV-Luc, PLGA/pSV-Luc
nanospheres, or PLGA/DC-Chol/pSV-Luc nanospheres were injected into rat spinal cords.
Fourteen days after injection, the PLGA/DC-Chol nanosphere group showed the highest level
of luciferase expression (Fig 4A and 4B). We injected PLGA/DC-Chol/pSV-Luc nanospheres
into the spinal cord to assay the distribution of luciferase expression following PLGA/DC-Chol
delivery. Luciferase positive cells were observed near the injected site in the spinal cord. (Fig
4C, 4D and 4E). Luciferase expression was detected both in beta III tublin–positive neurons
and GFAP-positive astrocytes in the site of the spinal cord injury (Fig 4C and 4D). Luciferase
positive cells observed SM-α actin positive arteriole (Fig 4E). These results suggest that PLGA/
DC-Chol/pSV-Luc nanospheres was delivery into the spinal cord, and that luciferase was
expressed in both the neurons and astrocytes in the spinal cord.
Angiogenesis and tissue regeneration
Immunostaining for SM-α actin revealed more extensive angiogenesis in injured spinal cords
of rats injected with VEGF-loaded PLGA/DC-Chol nanospheres compared with those of
other groups 4 weeks after injection (Fig 5A). Quantification of arteriole density revealed that
arteriole formation was significantly enhanced by injection of VEGF-loaded PLGA/DC-Chol
nanospheres compared with injection of PBS, naked VEGF pDNA, or PEI/pVEGF complex
(Fig 5B).
Fig 3. Apoptosis in the rat spinal cord. (A) Apoptotic activity at the injection site 24 h after injection. Nuclei
were stained with DAPI (blue). Apoptosis-positive nuclei were stained with FITC (green) using a TUNEL
staining method. Scale bars indicate 100 μm. (B) TUNEL-positive cell density at the injection site for naked
pDNA, PEI/pDNA, PLGA/pDNA, and PLGA/DC-Chol/pDNA groups. *p < 0.05 compared with naked, PLGA
nanospheres and PLGA/DC-Chol nanospheres
doi:10.1371/journal.pone.0147389.g003
DC-Chol/PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury
PLOS ONE | DOI:10.1371/journal.pone.0147389 January 29, 2016 8 / 14
Axonal growth was assessed by double staining with GFAP and NF 4 weeks after injection
of PBS, naked pVEGF, PEI/pVEGF, PLGA/pVEGF nanospheres, or PLGA/DC-Chol/pVEGF
nanospheres; areas positive for NF only were considered to indicate axonal regeneration
[25,26]. Double staining with GFAP and NF revealed smaller lesion areas after injection of
PLGA/DC-Chol nanospheres than after injection of PBS (Fig 6A). Areas positive for NF only
in lesion sites were observed for all groups, although those in the PBS-treated group were dis-
turbed due to linear glial scarring and large cavity formation. In the PLGA/DC-Chol nano-
sphere group, NF-positive axons were extensively present throughout the lesion site. Also,
PLGA/pVEGF nanospheres was able to significantly increase NF-positive area compared to
PBS treatment. Axonal regeneration in spinal cords injected with pVEGF-loaded PLGA/
DC-Chol nanospheres was significantly greater than that in PBS, naked VEGF, and PEI/VEGF
Fig 4. Gene expression in the rat spinal cord. (A, B) Luciferase activity in the rat spinal cord 14 days after
injection. *p < 0.05 compared with naked pLuci and PLGA/pLuci. # p < 0.05 compared with naked and PEI/
pDNA, + p < 0.05 compared with PEI/pDNA. Duble immunofluorescent staining for (C) beta III tublin (red),
luciferease (green) and betaIII tublin/luciferase merged cells (yellow) (D) GFAP (green), luciferase (red) and
GFAP/luciferase merged cells (yellow), (E) Smooth muscle α-actin (red), luciferase (green) and SM α-actin/
luciferase merged cells(yellow) in spinal cord. The arrows indicate cells of luciferase expression and beta III
tublin positive cells, GFAP positive cells or sm-α actin positive cells. Scale bars indicate 50 μm.
doi:10.1371/journal.pone.0147389.g004
Fig 5. Angiogenesis after injection of VEGF-loaded PLGA/DC-Chol nanospheres. (A)
Immunofluorescent staining for SM-α actin in injured spinal cords 4 weeks after injection. Scale bars indicate
100 μm at 100× and 20 μm at 400× (B) Quantification of arteriole density in injured spinal cords. *p < 0.05 vs.
PBS, naked VEGF, or PEI/VEGF. #p < 0.05 vs. PBS.
doi:10.1371/journal.pone.0147389.g005
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groups (Fig 6B), indicating that PLGA/DC-Chol nanospheres encapsulating VEGF pDNA
could improve functional recovery as a result of enhanced angiogenesis and tissue restoration
via axonal outgrowth in lesion areas.
Recovery of locomotor function
Rats in the PLGA/DC-Chol/VEGF and PLGA/VEGF groups showed better recovery of loco-
motor function 2 weeks after injection compared with rats in the other groups (Fig 6C). Rats
injected with PLGA/DC-Chol nanospheres encapsulating VEGF pDNA (n = 5, average score:
13.6±2.25) showed significantly greater functional recovery compared with rats injected with
PLGA/VEGF nanospheres (n = 5, average score: 10.2±2.27), PEI/VEGF complex (n = 5, aver-
age score: 8.6±2.41), naked VEGF (n = 5, average score: 9.2±3.35), or PBS (n = 5, average score:
6.6±1.55) 4 weeks after injury. This enhanced functional recovery in rats treated with PLGA/
DC-Chol nanospheres encapsulating VEGF pDNA may be a result of increased neovasculari-
zation and restoration of axonal outgrowth.
Discussion
We investigated methods for preparing cationic PLGA nanospheres as non-viral vectors for
gene delivery. We found that nanospheres made of PLGA/DC-Chol were less cytotoxic than
PEI both in vitro and in vivo. PLGA/DC-Chol nanospheres were taken up by cells 6 and 24 h
after injection, and injection of PLGA/DC-Chol nanospheres resulted in greater and longer-
lasting gene expression compared with PEI both in vitro and in vivo. PLGA/DC-Chol nano-
spheres encapsulating VEGF pDNA enhanced axon growth and angiogenesis in injured rat spi-
nal cords. VEGF-loaded PLGA/DC-Chol nanospheres not only improved the regeneration of
Fig 6. Axonal growth at lesion site and functional recovery 4 weeks after injury and injection. (A)
Double immunostaining with GFAP (red) and NF (green). Scare bar indicates 100 μm. (B) Quantification of
NF optical density of regenerated area. *p < 0.05 vs. PBS, naked VEGF, and PEI/VEGF. #p < 0.05 vs. PBS.
(C) Effect of VEGF-loaded PLGA/DC-Chol nanospheres on recovery of locomotor function. BBB score was
significantly greater in the PLGA/DC-Chol nanosphere group (n = 5) compared to PLGA/VEGF (n = 5), PEI/
VEGF (n = 5), naked VEGF (n = 5), and PBS (n = 5) 3 and 4 weeks after injury. *p < 0.05 for PLGA/DC-Chol
vs. PBS, naked VEGF, and PEI/VEGF groups.
doi:10.1371/journal.pone.0147389.g006
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injured spinal cord tissue but also promoted the recovery of locomotor activity in adult rats
with spinal cord injury.
The use of PLGA/DC-Chol nanospheres as gene delivery vehicles provides several advan-
tages over other methods, including increased cellular uptake and higher transgene expression.
We found that the incorporation of greater amounts of the cationic lipid DC-Chol into the
PLGA matrix significantly reduced particle size and increased nanosphere zeta potential
(Table 1). This phenomenon of decreasing particle size with increasing amounts of cationic
polymer has also been observed using DOPAP and PEI [17,27] and may be due to reduced
interfacial tension between the particle surface and the aqueous medium. We also found that
the zeta potential of PLGA nanospheres transitioned from negative to positive with increasing
amounts of DC-Chol. These positive charges on nanosphere surfaces could enhance their adhe-
sion to negatively charged cell surfaces, thereby facilitating their entry into cells by endocytosis
[21]. Increasing amounts of DC-Chol, a cationic cholesterol derivative, in the PLGAmatrix sig-
nificantly increases the zeta potential of nanospheres, and pDNA is incorporated into the PLGA/
DC-Chol nanospheres as the result of an electrostatic interaction between negatively charged
pDNAwith positively charged PLGA/DC-Chol nanoparticles [20,21]. The amount of cellular
uptake of PLGA/DC-Chol nanospheres was higher than that of unmodified PLGA nanospheres
(S1 Fig). Moreover, the encapsulation efficiency of pDNA and gene expression of PLGA/
DC-Chol nanospheres was increased by the presence of DC-Chol (Fig 2B and 2C).
The use of PLGA/DC-Chol nanospheres allowed for long-term transgene expression, with
the sustained release of pDNA from nanospheres for at least 14 days (Fig 2). We found that, 7
days after transfection, the level of pDNA gene expression was higher for PEI than for PLGA
and PLGA/DC-Chol nanospheres. Fourteen days after transfection, however, this trend was
reversed, likely due to sustained pDNA release from degraded PLGA via hydrolysis [14]. Previ-
ous studies have also showed sustained release of pDNA and gene expression from PLGA
nanospheres [7,12]. This longer gene expression from PLGA nanospheres may be due to the
protection of pDNA from nuclease degradation and the prolongation of pDNA half-life after
cell uptake [12,28]. Furthermore, we found that DC-Chol modification enhanced gene expres-
sion from PLGA/DC-Chol nanospheres both in vitro and in vivo (Fig 2B and 2C). Also, PLGA
DC-Chol nanospheres loaded with pDNA showed higher transgene expression than naked
pDNA in vivo. Therefore, PLGA/DC-Chol nanospheres could be used as vectors for the sus-
tained release of pDNA and the long-term expression of genes.
Compared to PEI, treatment with PLGA/DC-Chol nanospheres led to improved cell viabil-
ity of mNSCs and rat spinal cord tissue. Our results show that DC-Chol-modified PLGA nano-
spheres have a better safety profile than PEI. Also, the positive charges of PLGA/DC-Chol
nanospheres did not reduce cell viability or increase apoptosis compared with unmodified
PLGA nanospheres (Figs 2A and 3). Liposomes and cationic polymer are major non-viral vec-
tors that have been applied in various stages of clinical trials [19]. Although liposomes have
advantages such as low immunogenicity and ease of preparation, their use is limited due seri-
ous cytotoxic side effects, low transfection efficiency, and instability in serum [29]. Also,
although PEI, a cationic polymer, has been used as a gene delivery carrier because of its high
transfection efficiency, its high cytotoxicity severely limits its application in vivo [30]. By con-
trast, PLGA is a biocompatible and biodegradable polymer that is approved for human applica-
tions. Also, several studies have implanted PLGA nerve conduit or PLGA scaffold for
regeneration of spinal cord after injury and evaluated the interaction of host tissue [31–33].
Implantation of the PLGA scaffold with cells promoted long-term improvement in function
[31,34]. Although degradation of PLGA is created an acidic environment, PLGA nanoparticles
did not impact the proliferation of astrocytes or the survival of neuron in vitro [35]. In the pres-
ent study, TUNEL analysis did not show significant evidence of tissue apoptosis caused by
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PLGA nanospheres. Our results show that DC-Chol-modified PLGA nanospheres have a better
safety profile than PEI. Also, the positive charges of PLGA/DC-Chol nanospheres did not
reduce cell viability or increase apoptosis compared with unmodified PLGA nanospheres (Figs
2A and 3).
Our findings indicate that nanospheres encapsulating VEGF pDNA could serve as efficient
therapeutic vehicles for VEGF gene delivery to spinal cord injury, as their injection induced long-
term VEGF expression and increased angiogenesis. Angiogenesis has been closely related func-
tion recover after CNS disease such as strock or SCI due to enough blood supply and oxygen sup-
ply for neural regeneration [36,37]. Increased angiogenesis after SCI induces endogenous
recovery mechanisms, neuron survival and promote functional recovery [38]. Prior studies report
that high VEGF expression and angiogenesis improves oxygen supply to the spinal cord after
injury and increases axonal outgrowth and functional recovery [25,26]. Consistent with these
previous studies, the present study confirms that nanospheres encapsulating VEGF pDNA can
stimulate angiogenesis in the injured spinal cord and lead to recovery of locomotor function.
In summary, DC-Chol-modified PLGA nanospheres were less cytotoxic than PEI in vitro
and in vivo. Also, VEGF gene delivery to the injured spinal cord using DC-Chol-modified PLGA
nanospheres resulted in more angiogenesis and greater therapeutic effects 4 weeks after treatment
compared with PBS or VEGF gene delivery via PEI or unmodified PLGA nanospheres. Further
studies will be necessary to assess the clinical utility of this method, particularly those that are
longer (i.e., more than 2 months) in duration. Additional studies should assess functional recov-
ery using electrical measurements and VEGF effect post-injection of plasmid encapsulated
PLGA/DC-Col nanospheres after spinal cord injury. Future studies will extend the capabilities of
PLGA/DC-Chol nanospheres using the combined plasmid therapy such as BDNF and FGF in
spinal cord injury models. Our findings suggest that DC-Chol-modified PLGA nanospheres
could potentially serve as vehicles for gene delivery for spinal cord injury.
Supporting Information
S1 Fig. Cellular uptake of nanospheres. Cellular uptake of nanospheres. Confocal micro-
scopic images showing cellular uptake of PLGA or PLGA/DC-Chol nanospheres tagged with
6-coumarin (green) by mNSCs after 6 h (Top) or 24 h (Bottom) of incubation. Nuclei were
stained with DAPI (blue) Scale bar indicates 10 μm.
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